A significant minority of major depressive disorder patients don’t respond to currently available antidepressant medication. A newly approved treatment, based on the "club drug" ketamine, could change that. In a session at the British Neuroscience Association’s Festival of Neuroscience 2019, the potential mechanisms of ketamine’s antidepressant action were put under examination.
Analytical Cannabis speaks to the Queen of Consciousness herself about cannabis, campaigning, and creating a leading foundation for drug science and research.
Researchers just ran the first ever pre-registered scientific study on the microdosing of psychedelics and found some very promising results.
Chris Timmermann, from The Psychedelic Research group at Imperial College London studies the action of psychedelics on the brain and their potential as therapeutics. This article reviews their research and their implications.